Observational studyBMC cardiovascular disorders2026
Elevated plasma TMAO levels associated with all-cause mortality in CAD patients in South China.
Observational study in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundCoronary artery disease (CAD) is a prevalent cardiovascular condition worldwide. Trimethylamine N-oxide (TMAO), a metabolite produced by gut microbiota, plays a crucial role in the pathogenesis and progression of CAD. However, the association between plasma TMAO and all‑cause mortality in Chinese CAD patients remains to be fully explored.
methodsIn this observational cohort study, 389 hospitalized CAD patients, confirmed via coronary angiography at Xiangya Hospital in 2022, were enrolled. Plasma TMAO levels were measured using liquid chromatography-tandem mass spectrometry. All-cause mortality events were identified through telephone interviews, hospital outpatient visits, and official hospital records, conducted semi-annually. Kaplan-Meier analysis and Cox regression analysis were employed to investigate the relationship between TMAO levels and all-cause mortality.
resultsAmong 364 CAD patients who completed the median follow-up period of 39 months (IQR: 37-42 months), 40 patients (11.0%) experienced all-cause mortality. Patients with elevated TMAO levels, based on the optimal cutoff value of 317.62 ng/mL, had a significantly higher mortality rate compared to those with lower levels (P < 0.0001). After adjusting for conventional risk factors, including diabetes, elevated TMAO levels showed a significant association of all-cause mortality (hazard ratio [HR] 2.657; 95% CI: 1.389 to 5.084; P = 0.003).
conclusionsElevated plasma TMAO levels are significantly associated with increased all-cause mortality over a median follow-up of 39 months in CAD patients from South China.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.